Showing results (161-170 of 177) with videos related to
Sort By:
Pageof 18
Bone Marrow Transplantation|June 19, 2025
Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AMLGuillaume Dachy, Myriam Labopin, Gérard Socié, et al.American Journal of Hematology|June 10, 2024
Comparable relapse incidence after unrelated allogeneic stem cell transplantation with post-transplant cyclophosphamide versus conventional anti-graft versus host disease prophylaxis in patients with acute myeloid leukemia: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Maud Ngoya, Jacques-Emmanuel Galimard, et al.Bone Marrow Transplantation|December 24, 2025
The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutationsIman Abou Dalle, Jacques-Emmanuel Galimard, Xavier Poire, et al.American Journal of Hematology|April 24, 2024
Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationYishan Ye, Myriam Labopin, Socié Gérard, et al.Journal of Applied Physiology (Bethesda, Md. : 1985)|March 11, 2021
Time course and magnitude of ventilatory and renal acid-base acclimatization following rapid ascent to and residence at 3,800 m over nine daysJordan D Bird, Jack K Leacy, Glen E Foster, et al.Ebiomedicine|January 25, 2021
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trialsYunda Huang, Logashvari Naidoo, Lily Zhang, et al.The Lancet. HIV|June 5, 2020
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trialRaphael J Landovitz, Sue Li, Joseph J Eron, et al.Hemasphere|June 14, 2024
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysisMaeve A O'Reilly, William Wilson, David Burns, et al.Haematologica|June 19, 2025
TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated versus haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationLin Li, Yishan Ye, Jacques-Emmanuel Galimard, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline FindingsNyaradzo M Mgodi, Simbarashe Takuva, Srilatha Edupuganti, et al.Pageof 18